Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Operating Leases (2022 - 2025)

Cytek Biosciences' Operating Leases history spans 4 years, with the latest figure at $14.0 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 85.94% year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, up 85.94%, while the annual FY2025 figure was $14.0 million, 85.94% up from the prior year.
  • Operating Leases reached $14.0 million in Q4 2025 per CTKB's latest filing, down from $16.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $17.4 million in Q2 2025 to a low of $7.4 million in Q1 2025.
  • Average Operating Leases over 4 years is $11.6 million, with a median of $11.2 million recorded in 2023.
  • Peak YoY movement for Operating Leases: plummeted 37.81% in 2023, then soared 113.85% in 2025.
  • A 4-year view of Operating Leases shows it stood at $15.2 million in 2022, then tumbled by 37.81% to $9.5 million in 2023, then dropped by 20.33% to $7.6 million in 2024, then soared by 85.94% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Operating Leases are $14.0 million (Q4 2025), $16.6 million (Q3 2025), and $17.4 million (Q2 2025).